Actualités de Switzerland

03.11.2016 – 15:01
Helsinn Healthcare SA
Helsinn Group and MEI Pharma Announce Long-Term Survival and Response Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia Accepted for Oral Presentation at Upcoming American Society of Hematology Annual Meeting
Lugano, Switzerland and San Diego (ots/PRNewswire) - Data to be presented on December 3, 2016; Abstract now available online Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel ...
plus
10.10.2016 – 08:01
Helsinn Healthcare SA
Helsinn Group Introduces Helsinn Investment Fund
Lugano, Switzerland (ots/PRNewswire) - ~ Helsinn Group creates new investment fund in 40th anniversary year ~ ~ The new fund will focus on supporting early-stage investment opportunities in areas of high unmet patient need ~ Helsinn, the Swiss Pharmaceutical Group focused on building quality cancer care, today introduces Helsinn Investment Fund S.A. ("the Fund"), a fund focused on early-stage investment opportunities in ...
plus
06.10.2016 – 14:02
Tillotts Pharma AG
Tillotts Pharma AG's Parent Company Zeria Pharmaceutical Receives Approval for Zentacort® 3mg Capsules in Japan
Rheinfelden, Switzerland (ots/PRNewswire) - Zeria Pharmaceutical Co., Ltd. has received the approval for a new drug application for Zentacort 3mg capsules from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the indication of the improvement of Crohn's Disease (CD). Following the acquisition of the ...
plus
25.07.2016 – 08:01
Shire Pharmaceuticals Group Plc
ONIVYDE® Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas Who Have Progressed Following Gemcitabine Based Therapy
Zug, Switzerland (ots/PRNewswire) - The positive opinion is based on a pivotal Phase 3 study showing that ONIVYDE combined with chemotherapy significantly increased overall survival (OS) in patients with metastatic pancreatic cancer after previous gemcitabine based therapy Shire plc (LSE: SHP, NASDAQ: SHPG) today ...
plus
21.07.2016 – 13:01
Shire Pharmaceuticals Group Plc
Shire Launches Pediatric Indication for Immunodeficiency Treatment HyQvia in Europe
Zug, Switzerland (ots/PRNewswire) - HyQvia (Human Normal Immunoglobulin 10% and Recombinant Human Hyaluronidase) is the only subcutaneous IG treatment for primary and certain secondary immunodeficiencies that can be administered in one site, once a month (up to every four weeks) Shire plc (LSE: SHP, NASDAQ: SHPG) is launching a pediatric indication for HyQvia (Human ...
plus
07.07.2016 – 08:01
Shire Pharmaceuticals Group Plc
Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS)
Zug, Switzerland (ots/PRNewswire) - This press release is intended for a global audience. First therapy indicated in the EU for use in patients aged one year and above with SBS, a rare gastrointestinal condition Shire (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission has granted extension of ...
plus

27.06.2016 – 10:02
Domaine Clarence Dillon
Clarendelle, Inspired by Haut-Brion & Montreux Jazz Festival, Where Legends Inspire Young Talent Present: Clarendelle, Exclusive Official Sponsor of the Montreux Jazz Festival
Montreux, Switzerland (ots/PRNewswire) - On the occasion of the 50th edition of the Montreux Jazz Festival, Domaine Clarence Dillon and Clarence Dillon Wines have signed a partnership agreement for the next three years by which Clarendelle is proud to become an exclusive foreign wines partner of the Montreux Jazz ...
plus
10.06.2016 – 21:13
Shire Pharmaceuticals Group Plc
Shire Announces Completion of Decentralized Procedure in Europe for Immunoglobulin Treatment Cuvitru
Zug, Switzerland (ots/PRNewswire) - - Cuvitru (IG 20mg/ml solution for subcutaneous injection) builds on company's broad portfolio of IG treatments gained through combination with Baxalta - New option to treat primary and certain secondary immunodeficiencies can help meet patient needs related to number of infusion ...
plus
07.06.2016 – 17:17
Debiopharm International SA
Debiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1143 in Ovarian Cancer
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm today announced the start of a phase II clinical trial for Debio 1143 in combination with standard of care Carboplatin and Paclitaxel in Epithelial Ovarian Cancer Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global ...
plus
02.06.2016 – 09:02
Debiopharm International SA
FDA Grants Orphan Drug Designation to Debiopharm International SA's IAP Inhibitor Debio 1143 in the Treatment of Ovarian Cancer
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), a Swiss-based company, part of Debiopharm Group(TM), today announced that the FDA Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation to Debio 1143 for treatment of ovarian cancer. Orphan Drug Designation ...
plus
27.05.2016 – 08:01
Shire Pharmaceuticals Group Plc
Shire Receives Positive CHMP Opinion in Europe for Revestive® (Teduglutide) for Paediatric Patients with Short Bowel Syndrome
Zug, Switzerland (ots/PRNewswire) - Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the extension of the approval of Revestive[®*] (teduglutide) 5 mg powder and solvent for ...
plus
04.05.2016 – 15:13
JTI Japan Tobacco International AG
CJEU Rulings on Tobacco Products Directive Bring Additional Confusion
Geneva, Switzerland (ots/PRNewswire) - The Directive's Aim is to Harmonize Regulations - Not Disrupt the Free Movement of Goods Across the EU Just two weeks before the Tobacco Products Directive (TPD2) comes into force in the 28 EU Member States, the Court of Justice of the European Union (CJEU) has rejected tobacco manufacturers' claims against TPD2. (Logo: ...
plus

17.04.2016 – 08:01
Novo Nordisk
Novo Nordisk mark World Haemophilia Day and unveil the 2016 HERO Research Grant
Zürich, Switzerland (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Today, on World Haemophilia Day, Novo Nordisk announces that the grant scheme to support and encourage research projects focused on the psychosocial issues faced by people with haemophilia is open for ...
plus
15.04.2016 – 09:01
Debiopharm International SA
Debiopharm International SA Announces Presentation at AACR of Non-clinical Data Relating to its Targeted Investigational Compound Debio 1347/CH5183284, a Selective FGFR 1,2,3 Inhibitor
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), a Swiss-based company, part of Debiopharm Group(TM), today announces that non-clinical data on the clinical-stage investigational compound Debio 1347/CH5183284 (FGFR 1,2,3 inhibitor) will be presented at the 2016 Annual Meeting of the ...
plus
08.04.2016 – 09:01
Debiopharm International SA
Debiopharm International SA to Present the Latest Findings on Debio 1450 at ECCMID
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm will be present at ECCMID in Amsterdam to share new data supporting the clinical development of its first in class Staphylococcus-selective antibiotic Debio 1450 Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced three communications ...
plus
07.03.2016 – 16:52
Medtronic
Medtronic Avila(TM) Interbody Fusion Device Launched in Europe
Tolochenaz, Switzerland (ots/PRNewswire) - European innovation delivers titanium family of cages to support twin surgical objectives of bone fusion and sagittal realignment for improved patients' outcomes. Medtronic PLC (NYSE: MDT), the global leader in medical technology, today announced the launch of AVILA(TM), its new family of interbody fusion devices for L2-S1 levels in open and minimally invasive ALIF and OLIF ...
plus
04.03.2016 – 09:01
Debiopharm International SA
Debiopharm International SA Has Won Its Patent Infringement Suit for Elplat® Against Nippon Kayaku Co., Ltd.
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company today announces that the Tokyo District Court granted Debiopharm an overall victory for the first instance demanding the suspension of patent infringement of ...
plus
13.01.2016 – 16:01
Debiopharm International SA
Debiopharm International SA and EORTC Announce a Collaboration to Investigate Triptorelin for Treatment of Salivary Gland Cancers
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced a collaboration in order to supply triptorelin pamoate 3.75 mg 1-month formulation for patients suffering from salivary gland cancer ...
plus

11.01.2016 – 16:01
Helsinn Healthcare SA
Helsinn Celebrates its 40th Anniversary
Lugano, Switzerland (ots/PRNewswire) - ~ 40 years helping patients achieve a better quality of life ~ Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, is delighted to launch its 40th anniversary celebrations in San Francisco, US, at the time of the JP Morgan 34th Annual Healthcare Conference. Helsinn believes its core values of respect, integrity and quality have underpinned four decades of ...
plus
11.01.2016 – 15:31
Debiopharm International SA
Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce Their US Commercialization Partnership for Triptorelin in Central Precocious Puberty
Lausanne, Switzerland and Atlanta (ots/PRNewswire) - Arbor Pharmaceuticals to commercialize triptorelin in sustained-release formulation for the orphan indication central precocious puberty Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, and ...
plus
08.12.2015 – 09:01
Debiopharm International SA
EMA Grants Orphan Drug Designation to Debiopharm International SA's IAP Inhibitor Debio 1143 in the Treatment of Ovarian Cancer
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to Debio 1143 for treatment of Ovarian Cancer affecting around 154 ...
plus
07.12.2015 – 09:04
Debiopharm International SA
United Laboratories Inc. and Debiopharm International SA Announce the Launch of Pamorelin® LA in the Philippines
Mandaluyong, Philippines and Lausanne, Switzerland (ots/PRNewswire) - Pamorelin® one-, three- and six-month dosing option now available to patients in the Philippines United Laboratories Inc. (Unilab) and Debiopharm International SA (Debiopharm) announce the signature of an exclusive agreement for the distribution ...
plus
24.11.2015 – 09:01
Debiopharm International SA
Debiopharm International SA's Partner Yakult Honsha Co, Ltd. Announces Elplat® Approbation in Gastric Cancer in Japan
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, is proud to congratulate its partner Yakult's commitment in obtaining approval for a supplemental new drug application for Elplat® in postoperative ...
plus
03.11.2015 – 09:03
Debiopharm International SA
Debiopharm International SA Presents Positive Preliminary Results From Phase 1 Trials in the Development of the IAP Inhibitor Debio 1143 at the 27th EORTC-NCI-AACR Symposium in Boston
Lausanne, Switzerland (ots/PRNewswire) - Recommended Dose reached and early signs of efficacy seen Debiopharm International SA (Debiopharm) - part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company - today announced significant milestones in the clinical development of the SMAC mimetic ...
plus

01.10.2015 – 14:02
Shire Pharmaceuticals Group Plc
Shire Announces Winners of Spotlight on Gaucher Film Contest to Mark International Gaucher Day
Zug, Switzerland (ots/PRNewswire) - Shire plc is pleased to announce the winner and runner up of the Spotlight on Gaucher film contest on the occasion of International Gaucher Day (IGD). The film contest, which was supported by the European Gaucher Alliance (EGA), encouraged people whose lives have been touched by Gaucher disease to share a video to raise awareness of ...
plus
21.09.2015 – 08:01
Shire Pharmaceuticals Group Plc
Shire Receives European Approval for INTUNIV®? (Guanfacine Hydrochloride Prolonged Release Tablets) as a Non-stimulant ADHD Treatment for Children and Adolescents
Zug, Switzerland (ots/PRNewswire) - The first selective alpha-2A adrenergic receptor agonist licensed for the treatment of ADHD in the EU Shire today announced that the European Commission granted Marketing Authorisation for once-daily, non-stimulant INTUNIV(R) (guanfacine hydrochloride prolonged release ...
plus
16.06.2015 – 14:02
Debiopharm International SA
Debiopharm International SA Acquires FibroTrap Sample Processing Technology from Spinomix
Lausanne, Switzerland (ots/PRNewswire) - - Applicable to a wide variety of sample types to isolate bacteria, viruses, tumor cells, etc. - FibroTrap improves sensitivity and shortens time taken from sample collection to results - Spinomix to focus on the development of its flagship MagPhase technology Debiopharm ...
plus
03.06.2015 – 08:02
Shire Pharmaceuticals Group Plc
Shire Receives European Approval to Use Resolor® (prucalopride) in Men for the Symptomatic Treatment of Chronic Constipation
Zug, Switzerland (ots/PRNewswire) - For Release in Europe Only - Resolor was approved in 2009 in Europe for use in women for the symptomatic treatment of chronic constipation in whom laxatives fail to provide adequate relief[1] Shire plc announced today that Resolor (prucalopride) has been approved by the European ...
plus
23.04.2015 – 08:32
Debiopharm International SA
Debiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1450 in Staphylococcal Skin Infections
Lausanne, Switzerland (ots/PRNewswire) - One year after the initiation of Phase I, Debiopharm announced the start of clinical phase II for Debio 1450 in ABSSSI and presentation of new data at ECCMID Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical ...
plus
16.04.2015 – 14:02
Debiopharm International SA
Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm presents preclinical results for 2 anti-cancer targeted therapies Debio 1143 and Debio 1347 Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet ...
plus

Précédent567891011121314Suivant